Test Price
2,500 AED✅ Home Collection Available
Minimal Residual Disease (MRD) Monitoring for Multiple Myeloma | DNA Labs UAE
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139).
- Sample Collection: Hospital Extraction Only – Sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety.
- Clinical Guidance: Telephonic Post-Test Clinical Guidance for result interpretation with our senior oncology consultant.
- Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731.
All services are fully compliant with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 concerning health data.
Test Overview & Methodology
Minimal Residual Disease (MRD) monitoring employs highly sensitive multiparametric flow cytometry to detect residual myeloma cells at levels as low as 0.01% after therapy, enabling precise treatment tailoring. Used by oncologists and hematologists, it is the gold standard for assessing remission depth.
| Feature | Our MRD Test (Multiparametric Flow Cytometry) | Conventional Morphology (No MRD) |
|---|---|---|
| Precision / Sensitivity | Detects 1 cancer cell in 10,000 (0.01%) | Detects ≥5% abnormal cells (low sensitivity) |
| Methodology | 8‑color flow cytometry, ISO 9001:2015 accredited | Manual microscopic slide review |
| Turnaround Time | 3 working days (sample by 9 am) | 5–7 working days |
Physician Insight & Safety Protocols
“I understand the deep anxiety that follows cancer treatment. MRD monitoring is a beacon of precision; a single residual cell among ten thousand can be found. A negative MRD result often signals prolonged remission, but each patient's journey is unique and requires holistic clinical correlation.”
— Mr. Prabhakar Reddy Kalathoor, Specialist Diagnostic Radiology, DHA Registration ID: 61713011
Advisory: Medication & Treatment Continuity
⚠️ Do not discontinue any prescribed medication, including anti‑CD38 therapy (e.g., daratumumab), without consulting your treating doctor. MRD results must be interpreted in the context of your entire clinical picture.
Exclusion Criteria & Emergency Red Flags
- Absolute contraindications: Refusal of procedure, severe uncorrected thrombocytopenia (<20 ×10⁹/L platelets) without transfusion support, known allergy to local anesthetic, active infection at puncture site.
- Seek emergency care if you experience: Fever >38.5°C within 24 hours of collection, persistent active bleeding, or signs of severe infection post‑collection.
Patient FAQ & Clinical Guidance
1. What does a negative MRD result mean for someone with multiple myeloma?
A negative MRD result indicates no detectable myeloma cells at a sensitivity of 0.01%, strongly predicting prolonged remission and improved survival. However, regular monitoring and clinical correlation remain essential.
2. How is the bone marrow sample collected for this MRD test?
Collection is a first‑pull bone marrow aspirate from the iliac crest under local anesthesia, ensuring minimal contamination and high sample quality. This is strictly performed within an accredited hospital setting.
3. Why is my anti‑CD38 therapy history critical before MRD testing?
Anti‑CD38 antibodies can mask the CD38 marker on myeloma cells, requiring alternative gating strategies to avoid false negatives. Your treating physician must provide this information on the test request form.
4. How long does it take to get results?
Turnaround time is 3 working days from sample receipt at the laboratory (if sample arrives by 9 am). Urgent clinical cases may be expedited upon request.
UAE Regulatory & Data Privacy Adherence
Compliance & Data Protection
- Data processing complies with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
- Clinical safety and patient consent are governed by Federal Decree-Law No. 4 of 2016 on Medical Liability.
- All laboratory procedures are performed under ISO 9001:2015 quality management standards and DHA regulatory oversight.
Clinical & Logistical Metadata
| Test Name | Minimal Residual Disease (MRD) Monitoring for Multiple Myeloma (Flow Cytometry) |
| Price (AED) | 2,500 AED |
| Turnaround Time | 3 working days |
| Sample Type / Matrix | Bone Marrow Aspirate (first pull) – Hospital Extraction Only |
| Methodology Used | 8‑color multiparametric flow cytometry, ISO 9001:2015 accredited |
| ICD-10-CM Code | C90.0 (Multiple Myeloma) |
| LOINC Code | 73753-8 (Minimal residual disease [Interpretation] in Bone marrow by Flow cytometry) |
| DHA Facility License & Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians